Head-to-head · WeighScore
MultiMedRx vs Omada Health
The verdict
MultiMedRx takes it — 57.6/100 to 55.6/100, but only just.
MultiMedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MultiMedRx is a LegitScript-certified telehealth platform with physical offices in Newport Beach, CA and Reno, NV. Omada Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | MultiMedRx | Omada Health |
|---|---|---|
| WeighScore | 57.6/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #394 | #436 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #394 · C
Strengths
- Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
- Two physical addresses listed: Newport Beach, CA and Reno, NV
- LegitScript seal present
- Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
- Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1
Where it loses points
- No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
- Monthly GLP-1 pricing isn't published — gated behind the consultation
- $100 consultation fee adds friction; many peers bundle it into the medication price
- Per-state availability not listed; only CA and NV offices disclosed
- Whether compounded GLP-1 is offered isn't clear — verify during intake
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.